Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ActiveSite Pharmaceuticals
Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
- Drug Delivery
- Drug Discovery Tools